Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Non-Current Assets (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Non-Current Assets readings, the most recent being $10.8 million for Q4 2023.

  • On a quarterly basis, Non-Current Assets fell 9.62% to $10.8 million in Q4 2023 year-over-year; TTM through Dec 2023 was $34.4 million, a 29.62% increase, with the full-year FY2023 number at $10.8 million, down 9.62% from a year prior.
  • Non-Current Assets hit $10.8 million in Q4 2023 for Elicio Therapeutics, down from $11.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $11.9 million in Q4 2022 to a low of $1.1 million in Q1 2023.
  • Median Non-Current Assets over the past 4 years was $5.5 million (2021), compared with a mean of $6.8 million.
  • The widest YoY moves for Non-Current Assets: up 138.48% in 2023, down 77.29% in 2023.
  • Elicio Therapeutics' Non-Current Assets stood at $5.0 million in 2020, then rose by 4.28% to $5.3 million in 2021, then surged by 126.87% to $11.9 million in 2022, then dropped by 9.62% to $10.8 million in 2023.
  • The last three reported values for Non-Current Assets were $10.8 million (Q4 2023), $11.1 million (Q3 2023), and $11.4 million (Q2 2023) per Business Quant data.